Down regulation of tumour biomarkers in colon cancer cells with IRNA PFK-1 plus metformin.
| Autor: | Reyes Serratos EA; Tecnologico de Monterrey, School of Engineering and Sciences, Campus Guadalajara, Mexico., Fernandez Castillo E, Sanchez Lopez L, Salinas Santander M, Orozco Nunnelly DA, Sanchez Salazar MG, Cervantes Astorga E, Rivas Estilla AM, Rios Ibarra CP |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Journal of B.U.ON. : official journal of the Balkan Union of Oncology [J BUON] 2021 Jul-Aug; Vol. 26 (4), pp. 1210-1218. |
| Abstrakt: | Purpose: Metformin has been widely used for the treatment of Type 2 Diabetes Mellitus (T2DM), hyperglycemia and polycystic ovarian syndrome. Recent studies have suggested the potential of this substance as a cancer chemopreventive agent. We evaluated the antitumoral effect of iRNA-PFK-1 and the combined therapy iRNA-PFK-1 + metformin in RKO p53-positive cells. Methods: mRNA levels of tumor suppressor genes AMPK, APC, and c-MYC, KRAS oncogenes were measured by qRT-PCR in RKO cells treated with 25 µM metformin alone or combined with iRNA-PFK-1, to evaluate the effect of both treatments. Results: At 72 h after treatment with either 25 µM metformin, 150 nM iRNA-PFK-1, or the combined treatment, the transcriptional levels of these biomarkers were decreased by ~73% (p˂0.05), ~99.9%, (p˂0.01), and ~76% (p˂0.05), respectively. Conclusion: These in vitro results support the potential therapeutic role of metformin and PFK-1 in the treatment of colon cancer via down-modulation of the expression of several important cancer biomarkers. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|